GlassScriptPhysician profile
Daniel Andres Casas
NPI 1124589593
$3,163.17
in general payments reported to CMS, 2019-2025
13 companies · $594 in 2025
The $594 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $76.50 · 2022: $523 · 2023: $886 · 2024: $1,083 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,512 · Education: $50.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,512.22 |
| Education | $50.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,341.01 | 2022-2025 | Rinvoq, Linzess, Viberzi |
| Regeneron Healthcare Solutions, INC. | $433.69 | 2023-2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $327.73 | 2022-2025 | Entyvio |
| Janssen Biotech, INC. | $252.45 | 2025 | Tremfya |
| Madrigal Pharmaceuticals | $235.55 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $188.43 | 2022-2024 | Xifaxan, Trulance, Plenvu |
| Ardelyx, INC. | $141.37 | 2022-2023 | Ibsrela |
| Genzyme Corporation | $81.63 | 2022-2024 | |
| Gilead Sciences, INC. | $76.50 | 2021 | |
| Exact Sciences Corporation | $25.45 | 2025 | Cologuard Collection Kit |
| Ferring Pharmaceuticals INC. | $22.30 | 2024 | Clenpiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.65 | 2023 | Cyltezo |
| Phathom Pharmaceuticals, INC. | $17.41 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Casas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.